2009
Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators
DuSell CD, Nelson ER, Wittmann BM, Fretz JA, Kazmin D, Thomas RS, Pike JW, McDonnell DP. Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators. Endocrinology 2009, 24: 33-46. PMID: 19901195, PMCID: PMC2802893, DOI: 10.1210/me.2009-0339.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAryl Hydrocarbon Receptor Nuclear TranslocatorBreast NeoplasmsCell DifferentiationCell LineCell Line, TumorChromatin ImmunoprecipitationDose-Response Relationship, DrugFemaleGene Expression ProfilingGene Expression RegulationHumansMaleMiceOsteoclastsReceptors, Aryl HydrocarbonReceptors, EstrogenRecombinant ProteinsSelective Estrogen Receptor ModulatorsTamoxifenConceptsSelective estrogen receptor modulatorsAryl hydrocarbon receptorEstrogen receptor modulatorsEstrogen receptorReceptor modulatorsBreast cancerAbsence of ERER-independent mannerAryl hydrocarbon receptor functionAgonist/antagonist activityActivity of drugsAhR target genesEstradiol metabolismPharmacological actionsOsteoclast differentiationTamoxifenTherapeutic efficacyActive metaboliteReceptor functionAntagonist activityHydrocarbon receptorCalcium signalingCellular proliferationPotential roleCellular model
2004
Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY. Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure 2004, 12: 2233-2247. PMID: 15576036, DOI: 10.1016/j.str.2004.10.004.Peer-Reviewed Original ResearchConceptsHigh-resolution crystal structuresInvariant glutamineHydrogen bondingCatalytic domainStructural basisStructural insightsIsoform-selective inhibitorsHydrolysis of cAMPHydrophobic residuesInhibitor bindingActive siteCrystal structureCocrystal structureHydrophobic clampLarge familyDifferent inhibitorsPhosphodiesterasesVariety of diseasesSelective PDE inhibitorsInhibitorsActivity of drugsPDE inhibitorsBondingEnzymeResiduesChapter 8 Prodrugs and Drug Delivery Systems
Silverman R. Chapter 8 Prodrugs and Drug Delivery Systems. 2004, 497-557. DOI: 10.1016/b978-0-08-051337-9.50013-4.Peer-Reviewed Original ResearchProdrug-to-drug conversionInactive compoundsActive drugBioprecursor prodrugsDrug designProdrug moleculesTransformation compoundsCompoundsDrug candidatesMolecular modificationsParent drugPhysicochemical propertiesMechanism of drug activityAbsorptionPharmacokinetic propertiesActivity of drugsPharmacodynamic propertiesTargeting of drugsConversion
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply